The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer
暂无分享,去创建一个
A. Giaccia | D. Chang | Vignesh Viswanathan | Q. Sodji | C. Li | M. Binkley | M. Olcina | Q. Le | Dhanya K. Nambiar | Deana Colburg | R. von Eyben | Deana R C Colburg
[1] E. Graves,et al. C3aR Signaling Inhibits NK-cell Infiltration into the Tumor Microenvironment in Mouse Models , 2021, Cancer Immunology Research.
[2] E. Nakakura,et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.
[3] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[4] D. Wainwright,et al. NK cell-based cancer immunotherapy: from basic biology to clinical development , 2021, Journal of Hematology & Oncology.
[5] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[6] Qiaofei Liu,et al. Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming , 2021, Frontiers in Cell and Developmental Biology.
[7] J. Boudreau,et al. NK cell infiltration is associated with improved overall survival in solid cancers: A systematic review and meta-analysis , 2020, Translational oncology.
[8] X. Lao,et al. Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer. , 2020, Gastroenterology.
[9] C. Robert. A decade of immune-checkpoint inhibitors in cancer therapy , 2020, Nature Communications.
[10] M. Karamouzis,et al. Immunotherapy for pancreatic cancer: A 2020 update. , 2020, Cancer treatment reviews.
[11] Cai Zhang,et al. Targeting Natural Killer Cells for Tumor Immunotherapy , 2020, Frontiers in Immunology.
[12] C. Pereira,et al. Is immunotherapy the holy grail for pancreatic cancer? , 2019, Immunotherapy.
[13] T. H. Nguyen,et al. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2019, The lancet. Gastroenterology & hepatology.
[14] Vanessa M. Hubbard-Lucey,et al. Immuno-oncology drug development goes global , 2019, Nature Reviews Drug Discovery.
[15] J. Kos,et al. Cysteine Cathepsins in Tumor-Associated Immune Cells , 2019, Front. Immunol..
[16] S. Antonia,et al. The NKG2A immune checkpoint — a new direction in cancer immunotherapy , 2019, Nature Reviews Clinical Oncology.
[17] Ash A. Alizadeh,et al. Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.
[18] C. Fisher,et al. The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma , 2018, Scientific Reports.
[19] A. Gonzalez-Perez,et al. NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival , 2018, Clinical Cancer Research.
[20] A. Koong,et al. Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance , 2018, Scientific Reports.
[21] Alexander H. E. Morrison,et al. Immunotherapy and Prevention of Pancreatic Cancer. , 2018, Trends in cancer.
[22] Ash A. Alizadeh,et al. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. , 2018, Methods in molecular biology.
[23] E. Smits,et al. CD56 in the Immune System: More Than a Marker for Cytotoxicity? , 2017, Front. Immunol..
[24] P. Storm,et al. Characterization of resident lymphocytes in human pancreatic islets , 2017, Clinical and experimental immunology.
[25] A. Akbarzadeh,et al. Prognostic implication of CD57, CD16, and TGF-β expression in oral squamous cell carcinoma. , 2016, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[26] T. Sayers,et al. NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype , 2015, The Journal of Immunology.
[27] M. Okoniewski,et al. Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. , 2015, Immunity.
[28] E. Golden,et al. Radiotherapy and immunogenic cell death. , 2015, Seminars in radiation oncology.
[29] Benjamin D. Smith,et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.
[30] P. Lapierre,et al. Transient Complement Inhibition Promotes a Tumor-Specific Immune Response through the Implication of Natural Killer Cells , 2013, Cancer Immunology Research.
[31] H. Klingemann. Cellular therapy of cancer with natural killer cells-where do we stand? , 2013, Cytotherapy.
[32] Cesar M. Castro,et al. Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection. , 2013, Neoplasia.
[33] W. Murphy,et al. Advantages and clinical applications of natural killer cells in cancer immunotherapy , 2013, Cancer Immunology, Immunotherapy.
[34] S. Demaria,et al. The convergence of radiation and immunogenic cell death signaling pathways , 2012, Front. Oncol..
[35] A. Cerwenka,et al. Natural Killer Cells and Solid Tumors , 2011, Journal of Innate Immunity.
[36] John D Lambris,et al. Complement: a key system for immune surveillance and homeostasis , 2010, Nature Immunology.
[37] Dale L. Greiner,et al. Humanized mice in translational biomedical research , 2007, Nature Reviews Immunology.
[38] K. Camphausen,et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.
[39] Eric J. Brown,et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor , 2005, Nature.
[40] Jung‐Ta Chen,et al. Prognostic significance of intratumoral natural killer cells in primary resected esophageal squamous cell carcinoma. , 2005, Chang Gung medical journal.
[41] A. Concha,et al. Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas , 2005, Cancer Immunology, Immunotherapy.
[42] R. Figlin,et al. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[43] S. Coca,et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. , 2002, Lung cancer.
[44] M. Giga,et al. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. , 2001, The Journal of thoracic and cardiovascular surgery.
[45] J. Adams,et al. Identification of a Selective Nonpeptide Antagonist of the Anaphylatoxin C3a Receptor That Demonstrates Antiinflammatory Activity in Animal Models , 2001, The Journal of Immunology.
[46] S. Natsugoe,et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma , 2000, Cancer.
[47] M. A. Sáez,et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma , 1997, Cancer.
[48] A. Andoh,et al. Local secretion of complement C3 in the exocrine pancreas: ductal epithelial cells as a possible biosynthetic site. , 1996, Gastroenterology.
[49] F. Schabel,et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. , 1984, Cancer research.
[50] R. Frade,et al. Inhibition of in vitro natural killer activity by the third component of complement: role for the C3a fragment. , 1982, Proceedings of the National Academy of Sciences of the United States of America.